Shiraz University of Medical SciencesMiddle East Journal of Cancer2008-67092220110401The Middle East Journal of Cancer Needs Your Continuous Support494941880ENFarhadHandjaniMiddle East Journal of Cancer, Shiraz University of Medical Sciences, Shiraz, IranJournal Article20131001https://mejc.sums.ac.ir/article_41880_168e889468c0e130117eefe99d3e6203.pdfShiraz University of Medical SciencesMiddle East Journal of Cancer2008-67092220110401Comparison of Docetaxel, Doxorubicin and Cyclophosphamide (TAC) with 5-Fluorouracil, Doxorubicin and Cyclophosphamide (FAC) Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Phase III Clinical Trial515841881ENShapourOmidvariDepartment of Radiation Oncology, Namazi Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran0000-0003-3656-9891SareHosseiniDepartment of Radiation Oncology, Namazi Hospital, Shiraz University of Medical
Sciences, Shiraz, IranYaghoubAshouriDepartment of Radiation Oncology, Namazi Hospital, Shiraz University of Medical
Sciences, Shiraz, IranSedighehTahmasebiDepartment of Surgery, Shahid Faghihi Hospital, Shiraz University of Medical Sciences,
Shiraz, Iran0000-0001-5880-2063AbdolrasoulTaleiDepartment of Surgery, Shahid Faghihi Hospital, Shiraz University of Medical Sciences,
Shiraz, Iran0000-0001-9111-3681HamidNasrolahiDepartment of Radiation Oncology, Namazi Hospital, Shiraz University of Medical
Sciences, Shiraz, IranNiloofarAhmadlooDepartment of Radiation Oncology, Namazi Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran0000-0003-3178-8577MansourAnsariDepartment of Radiation Oncology, Namazi Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran0000-0002-8249-1776AhmadMosalaeiDepartment of Radiation Oncology, Namazi Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran0000-0002-3986-8865MohammadMohammadianpanahDepartment of Radiation Oncology, Namazi Hospital, Shiraz University of Medical
Sciences, Shiraz, Iran0000-0001-9391-8977Journal Article20131001Background: The present study aimed to compare the rates of complete clinical and pathologic response to docetaxel, doxorubicin and cyclophosphamide (TAC) vs. 5-fluorouracil, doxorubicin and cyclophosphamide (FAC) as neoadjuvant chemotherapy in women with locally advanced breast cancer. Methods: One hundred women with pathologically confirmed newly diagnosed locally advanced (T3-T4 or N2-N3) breast cancer were randomly assigned to receive a median of four cycles of either 5-fluorouracil (600 mg/m2), doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) every three weeks or docetaxel (75 mg/m2), doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every three weeks followed by modified radical mastectomy. Complete clinical and pathologic response rates and toxicity were the primary and secondary outcome measures of the study.Results: Median age for all patients was 43.4 years (range 25-63 years). Patients in the TAC arm achieved a higher clinical (16%) response rate than those in the FAC arm (4%, P=0.046). The pathologic response rate was also higher in the TAC arm compared to the FAC arm [TAC (20%) vs. FAC (6%), P=0.037]. Estrogen receptor- negative status correlated with a higher clinical [TAC (19%) vs. FAC (4%), P=0.032] and pathologic [TAC (23%) vs. FAC (4%), P=0.011)] response rate in both arms. All patients generally tolerated treatment well, and treatment-related toxicities were manageable.Conclusion: Combined treatment with TAC led to higher rates of complete clinical and pathologic response with acceptable toxicity compared to FAC in patients with locally advanced breast cancer. However, further follow-up is needed to translate this response into improvements in survival.https://mejc.sums.ac.ir/article_41881_c17dec3b545f78d6da0e54b594943af3.pdfShiraz University of Medical SciencesMiddle East Journal of Cancer2008-67092220110401Survival Analysis in Patients with Non- metastatic Squamous Cell Carcinoma of the Urinary Bladder596441884ENMohamed I.El-SayedRadiation Therapy Department, South Egypt Cancer Institute, Assiut University,
Assiut, EgyptAhmed M.Abdel-RahimUrology Department, South Egypt Cancer Institute, Assiut University, Assiut, EgyptJournal Article20131001Background: We conducted a retrospective analysis to evaluate overall survival (OAS) and disease free survival (DFS) rates in patients with squamous cell carcinoma of the urinary bladder according to different prognostic factors.Methods: This retrospective study analyzed the medical records of patients with non-metastatic squamous cell carcinoma of the urinary bladder. All men underwent radical cystectomy and women underwent anterior pelvic exentration. Most patients had postoperative radiation therapy. The log-rank test examined differences in OAS and DFS rates.Results: The medical records of 106 patients were analyzed. The median follow- up from the date of enrollment was 30 months and ranged from 2 to 73 months. For the entire group, three-year OAS rates were 46.9% and DFS rates were 44%. For patients with P2 (tumor invasion into the muscularis propria) the three-year OAS rate was 53%, for P3 (tumor invasion into perivesical fat) it was 45% and 9% for P4 (tumor invasion into adjacent organs, pelvic wall or abdominal wall) The OAS rate was statistically significant in favor of P2 disease (P=0.0041). The three-year DFS rate was 50% for P2, 45% for P3 and 9% for P4 disease (P=0.0125). Administration of post-operative radiotherapy did not result in statistically significant improvement in three-year OAS and DFS rates.Conclusion: Survival rates were statistically significant and higher in patients with P2 and P3 disease compared to P4 disease. Adjuvant radiotherapy did not result in statistically significant survival improvementhttps://mejc.sums.ac.ir/article_41884_c33168036cbfb67f5925cdb43fbb6c2b.pdfShiraz University of Medical SciencesMiddle East Journal of Cancer2008-67092220110401Axillary Dissection in 44 Breast Cancer Patients without Seroma Formation656941886ENSedighehTahmasebiDepartment of Surgical Oncology, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran0000-0001-5880-2063ArminAmirianDepartment of Surgical Oncology, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, IranAbdolrasulTaleiDepartment of Surgical Oncology, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, IranJournal Article20131001<strong>Background: </strong>Seroma formation is a common problem following axillary dissection. It is probably caused by a local inflammatory response. Local steroids may prevent this problem by inhibiting inflammatory response at the wound site.<br /> <strong>Methods: </strong>This randomized prospective study was undertaken to evaluate the effect of local triamcinolone injection on seroma formation following axillary dissection. In addition, other wound complications were recorded. A total of 44 women who underwent axillary dissection were randomized to receive either 40 mg intracavitary triamcinolone (Group T, n=22) or saline (Group C, n=22) on their first postoperative visit. Drains were removed if 24-hour drainage was <strong>Results: </strong>No wound complications (including seroma formation) were observed in either group in four follow-up visits during the first month after surgery.<br /> <strong>Conclusion: </strong>In our study, in contrast to previous studies, seroma formation was not a common complication following axillary dissection. We could not evaluate the effect of local triamcinolone on seroma formation, although it apparently had no unfavorable effect on this potential complication. According to this study, axillary dissection can be a safe procedure if optimal surgical techniques and meticulous dissections are used, and if drain removal is timed appropriately.https://mejc.sums.ac.ir/article_41886_0ff8e832d29d5d74b3d488945b76dc39.pdfShiraz University of Medical SciencesMiddle East Journal of Cancer2008-67092220110401Epidemiology and Survival Analysis of Jordanian Female Breast Cancer Patients Diagnosed from 1997 to 2002718041882ENMohammedTarawnehNon-communicable Disease Directorate, Ministry of Health, Amman , JordanKamalArqoubNon-communicable Disease Directorate, Ministry of Health, Amman , JordanGhaziSharkasNon-communicable Disease Directorate, Ministry of Health, Amman , JordanJournal Article20131001Background: Breast cancer is the most common cancer among Jordanian women, yet survival data are scarce. This study aims to assess the observed five-year survival rate of breast cancer in Jordan from 1997 to 2002 and to determine factors that may influence survival. Methods: Data were obtained from the Jordan Cancer Registry (JCR), which is a population-based registry. From 1997-2002, 2121 patients diagnosed with breast cancer were registered in JCR. Relevant data were collected from JCR files, hospital medical records and histopathology reports. Patient's status, whether alive or dead, was ascertained from the Department of Civil Status using patients’ national numbers (ID). Statistical analysis was carried out using SPSS (version 10). Survival probabilities by age, morphology, grade, stage and other relevant variables were obtained with the Kaplan Meier method.Results: The overall five-year survival for breast cancer in Jordan, regardless of the stage or grade was 64.2%, meanwhile it was 58% in the group aged less than 30 years. The best survival was in the age group 40-49 years (69.3%). The survival for adenocarcinoma was 57.4% and for medullary carcinoma, it was 82%. The survival rate approximated 73.8% for well-differentiated, 55.6% for anaplastic, and 58% for poorly differentiated cancers. The five-year survival rate was 82.7% for stage I, 72.2% for stage II, 58.7% for stage III, and 34.6% for stage IV cancers.Conclusion: According to univariate analysis, stage, grade, age and laterality of breast cancer significantly influenced cancer survival. Cox regression analysis revealed that stage, grade and age factors correlated with prognosis, while laterality showed no significant effect on survival. Results demonstrated that overall survival was relatively poor. We hypothesized that this was due to low levels of awareness and lack of screening programs.https://mejc.sums.ac.ir/article_41882_08048abd038424e262793452afa8e004.pdfShiraz University of Medical SciencesMiddle East Journal of Cancer2008-67092220110401Nasopharyngeal Adenoid Cystic Carcinoma: Report of Five Cases and Treatment Outcome818541883ENBijanKhademiCancer Research Center, Department of Otolaryngology, Head and Neck Surgery, Khalili
Hospital, Shiraz University of Medical Sciences, Shiraz, IranHajarBahranifardDepartment of Otolaryngology, Head and Neck Surgery, Khalili Hospital, Shiraz
University of Medical Sciences, Shiraz, IranSayed HamedKabiriDepartment of Surgery, Namazi Hospital, Shiraz University of Medical Sciences,
Shiraz, IranSamirazRazzaghiDepartment of Radiation Oncology, Namazi Hospital, Shiraz University of Medical
Sciences, Shiraz, IranSeyed BasirHashemiDepartment of Otolaryngology, Head and Neck Surgery, Khalili Hospital, Shiraz
University of Medical Sciences, Shiraz, IranMahmoodShishegarDepartment of Otolaryngology, Head and Neck Surgery, Khalili Hospital, Shiraz
University of Medical Sciences, Shiraz, IranMohammadMohammadianpanahCancer Research Center, Department of Radiation Oncology, Namazi Hospital, Shiraz
University of Medical Sciences, Shiraz, Iran0000-0001-9391-8977Journal Article20131001Background: The present study aimed to report the characteristics and treatment outcomes of five patients with nasopharyngeal adenoid cystic carcinoma and a literature review.Methods: Between 2000 and 2009, five consecutive patients (4 men, 1 woman) were diagnosed with nasopharyngeal adenoid cystic carcinoma and treated at our institution. Three patients had stage IVa (T4N0M0) and two patients had stage III (T3N0M0) cancer. Primary treatment consisted of concurrent chemoradiation in three patients and radiotherapy alone in two patients. Surgery was limited to endoscopic biopsy for histological diagnosis.Results: Four patients achieved complete response during or after completion of treatment and remained free of disease for a median of 27 months. Four patients developed local recurrence 8-30 months after initial treatment. The fifth patient is alive and free of disease.Conclusion: The findings of the present study and literature review suggest that local failure is a major problem in adenoid cystic carcinoma of the nasopharynx.https://mejc.sums.ac.ir/article_41883_28ea93b205822509841ed3d5410f987a.pdfShiraz University of Medical SciencesMiddle East Journal of Cancer2008-67092220110401Simultaneous Laryngeal Squamous Cell Carcinoma and Papillary Thyroid Carcinoma879041885ENMohamad JavadAshrafPathology Department, Shiraz University of Medical Sciences, Shiraz, IranMehr SadatAlaviNuclear Medicine Department, Shiraz University of Medical Sciences, Shiraz, IranNegarAzarpiraOrgan Transplant Research Center, Pathology Department, Shiraz University of Medical
Sciences, Shiraz, Iran0000-0002-5549-0057BighanKhademiOtolaryngology Department,Shiraz University of Medical Sciences, Shiraz, IranJournal Article20131001The association of squamous cell carcinoma of the larynx with thyroid papillary carcinoma is an unusual finding. From 2004 to 2011, approximately 250 patients underwent laryngectomies due to squamous cell carcinoma of the larynx at the Otolaryngology Department of Khalili Hospital, affiliated with Shiraz University of Medical Sciences, Shiraz, Iran. In three patients, synchronous occurrence of squamous cell carcinoma and thyroid papillary carcinoma was found. Histopathologic study of the lymph nodes revealed metastatic papillary thyroid carcinoma in one case. We report three cases of thyroid papillary carcinoma incidentally found on histological examinations of resected thyroid lobes, as a procedure required for treatment of head and neck squamous cell carcinoma. In comparison, laryngeal squamous cell carcinoma needs more aggressive treatment than well-differentiated thyroid carcinoma. The prevalence of thyroid papillary carcinoma, as an incidental finding in our study was 0.01%. Therefore, preoperative evaluation of the thyroid gland by ultrasonog- raphy and fine needle aspiration biopsy of suspicious lesions is recommended in patients who are candidates for open laryngectomy.https://mejc.sums.ac.ir/article_41885_19473a59ef0b5bb3ac30c1bf5f9c3839.pdf